Disulfiram

Generic Name
Disulfiram
Brand Names
Antabuse
Drug Type
Small Molecule
Chemical Formula
C10H20N2S4
CAS Number
97-77-8
Unique Ingredient Identifier
TR3MLJ1UAI
Background

A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nau...

Indication

For the treatment and management of chronic alcoholism

Associated Conditions
Chronic Alcoholism
Associated Therapies
-
Clinical Trials
Related News

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

First Posted Date
2022-01-27
Last Posted Date
2024-10-17
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT05210374
Locations
🇺🇸

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Disulfiram
Drug: Placebo
First Posted Date
2020-10-20
Last Posted Date
2021-10-08
Lead Sponsor
ETICA
Target Recruit Count
140
Registration Number
NCT04594343
Locations
🇧🇷

ETICA, Salvador, Bahia, Brazil

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Disulfiram
Drug: Copper Gluconate
First Posted Date
2020-08-20
Last Posted Date
2023-03-13
Lead Sponsor
University of Utah
Target Recruit Count
2
Registration Number
NCT04521335
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

Phase 1
Completed
Conditions
Alcohol Disorders
Interventions
Drug: Perampanel Tablet
Drug: Disulfiram
First Posted Date
2020-08-06
Last Posted Date
2022-10-07
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
4
Registration Number
NCT04502589
Locations
🇺🇸

Virginia Commonwealth University Inst. for Drug and Alcohol Studies, Richmond, Virginia, United States

DISulfiram for COvid-19 (DISCO) Trial

Phase 2
Terminated
Conditions
Covid19
Interventions
Drug: Placebo
Drug: Disulfiram
First Posted Date
2020-07-24
Last Posted Date
2023-09-13
Lead Sponsor
University of California, San Francisco
Target Recruit Count
11
Registration Number
NCT04485130
Locations
🇺🇸

University of California San Francisco, Fresno, Fresno, California, United States

🇺🇸

San Francisco General Hospital, San Francisco, California, United States

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

First Posted Date
2020-02-11
Last Posted Date
2023-10-06
Lead Sponsor
National Cancer Institute, Slovakia
Registration Number
NCT04265274
Locations
🇸🇰

National Cancer Institute, Bratislava, Slovakia

Disulfiram and Cisplatin in Refractory TGCTs.

Phase 2
Completed
Conditions
Germ Cell Tumor
Interventions
Drug: Disulfiram
First Posted Date
2019-05-15
Last Posted Date
2023-10-04
Lead Sponsor
National Cancer Institute, Slovakia
Target Recruit Count
12
Registration Number
NCT03950830
Locations
🇸🇰

National Cancer Institute, Bratislava, Slovakia

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Phase 1
Completed
Conditions
Fatigue
Quality of Life
Interventions
Drug: Disulfiram
First Posted Date
2019-03-27
Last Posted Date
2023-06-05
Lead Sponsor
Research Foundation for Mental Hygiene, Inc.
Target Recruit Count
11
Registration Number
NCT03891667
Locations
🇺🇸

Lyme Research Center New York State Psychiatric Institute, New York, New York, United States

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

First Posted Date
2017-12-06
Last Posted Date
2024-10-03
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
15
Registration Number
NCT03363659
Locations
🇺🇸

Aurora Health Care, Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer

First Posted Date
2017-10-27
Last Posted Date
2024-07-03
Lead Sponsor
The Institute of Molecular and Translational Medicine, Czech Republic
Target Recruit Count
150
Registration Number
NCT03323346
Locations
🇨🇿

University Hospital Olomouc, Olomouc, Czechia

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy